Highlights
- Ind-Swift Laboratories Limited (NSE: INDSWFTLAB) rose 16.46% to ₹276.30 on August 11, 2026.
- The company reported June quarter total income of ₹193.71 crore and net profit of ₹24.44 crore.
- The stock opened at ₹266.00 and reached an intraday high of ₹284.68, with a low of ₹255.64.
- The price is trading well above its 50-day SMA of ₹207.01, maintaining an elevated medium-term structure.
- Trading volume stood at approximately 7.65 million shares, while VWAP was ₹278.31.
- Investors should monitor the recent high zone, RSI momentum, trading volumes and the distance from the 50-day SMA.
Overview
Ind-Swift Laboratories Limited (NSE: INDSWFTLAB) operates in the pharmaceutical and healthcare products industry. The stock advanced 16.46% to ₹276.30 on August 11, 2026, compared with the previous close of ₹237.24. It opened at ₹266.00, moved to an intraday high of ₹284.68 and touched a low of ₹255.64. VWAP stood at ₹278.31, while trading volume reached approximately 7.65 million shares. The latest move comes alongside the company's June quarter financial results, which provide a fresh fundamental reference for the market. The stock also remains significantly above its 50-day moving average, reflecting the strength of its recent price structure.
Fundamental View
For the quarter ended June 30, 2026, Ind-Swift Laboratories reported standalone total income of ₹193.71 crore, profit before tax of ₹32.43 crore and net profit of ₹24.44 crore. Earnings per share stood at ₹2.81. The June quarter results provide the latest financial information available for assessing revenue generation and profitability. Future monitoring will include revenue growth, margins, operating costs, cash flows and the consistency of earnings across subsequent quarters. The company's ability to maintain profitability while managing operating expenses and business expansion will remain relevant to its longer-term financial profile.
Technical View
The daily chart shows a sustained upward price structure, with the stock at ₹276.30 compared with its 50-day SMA of ₹207.01. The latest session extended the recent advance after the stock had consolidated around the ₹220.00-₹240.00 region. RSI 14 stands at 75.72, moving above the conventional 70 level and indicating elevated momentum. The stock recorded a high of ₹284.68, while volume of approximately 7.65 million shares indicates substantial trading activity. The current price remains considerably above the 50-day SMA, while the elevated RSI suggests that momentum has become extended following the latest move.
Key Technical Levels
Immediate support is around ₹255.64, based on the latest session low. The next support is near ₹237.24, corresponding to the previous close, while the 50-day SMA at ₹207.01 represents a broader technical reference. Immediate resistance is around ₹284.68, the latest intraday high. The next resistance level would depend on price discovery above this zone because the stock is trading near the upper portion of its recent chart range.
Risks to Watch
- RSI at 75.72 indicates an elevated momentum reading.
- The stock has moved substantially above its 50-day SMA, increasing the gap from the medium-term average.
- Sharp daily price movements can result in heightened short-term volatility.
- Sustaining recent earnings performance will be important for the fundamental outlook.
- A decline in trading volume or loss of recent price support could change the current technical structure.
Summary
Ind-Swift Laboratories (NSE: INDSWFTLAB) rose 16.46% to ₹276.30 following its latest June quarter financial results. The company reported total income of ₹193.71 crore, profit before tax of ₹32.43 crore and net profit of ₹24.44 crore, with EPS at ₹2.81. Technically, the stock remains well above its 50-day SMA of ₹207.01, while RSI at 75.72 indicates elevated momentum. The latest session also recorded substantial trading activity of approximately 7.65 million shares. Future monitoring will focus on earnings consistency, margins, volumes and price behaviour around ₹284.68, ₹255.64 and the 50-day SMA.
FAQs
Q: Why did Ind-Swift Laboratories rise today?
A: Ind-Swift Laboratories rose 16.46% to ₹276.30, with the move coming alongside the company's recently reported June quarter financial results.
Q: What were Ind-Swift Laboratories' June quarter results?
A: The company reported total income of ₹193.71 crore and net profit of ₹24.44 crore for the quarter ended June 30, 2026.
Q: What is Ind-Swift Laboratories' EPS?
A: The reported earnings per share for the June quarter was ₹2.81.
Q: What is the 50-day SMA of Ind-Swift Laboratories?
A: The 50-day SMA is ₹207.01, below the current market price of ₹276.30.
Q: What does the RSI indicate for Ind-Swift Laboratories?
A: RSI 14 is at 75.72, indicating elevated momentum and a reading above the conventional 70 level.